Tessa Romero
Stock Analyst at JP Morgan
(3.75)
# 683
Out of 4,883 analysts
62
Total ratings
43.75%
Success rate
11.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $13.79 | +298.84% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $33.36 | +58.87% | 5 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $26 → $30 | $20.88 | +43.68% | 7 | Jun 6, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $4.54 | +120.26% | 2 | May 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $8.18 | +107.82% | 5 | Mar 21, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $10.93 | +247.67% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $0.90 | +1,575.42% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $10.85 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $35.48 | -12.63% | 5 | Oct 14, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $9.49 | +205.58% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $31 | $12.60 | +146.03% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $35.21 | +30.66% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $4.23 | +65.48% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $31.83 | +72.79% | 2 | Apr 25, 2023 |
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $13.79
Upside: +298.84%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $33.36
Upside: +58.87%
ACADIA Pharmaceuticals
Jun 6, 2025
Maintains: Overweight
Price Target: $26 → $30
Current: $20.88
Upside: +43.68%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $4.54
Upside: +120.26%
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $8.18
Upside: +107.82%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $10.93
Upside: +247.67%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $0.90
Upside: +1,575.42%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $10.85
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $35.48
Upside: -12.63%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $9.49
Upside: +205.58%
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $12.60
Upside: +146.03%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $35.21
Upside: +30.66%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $4.23
Upside: +65.48%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $31.83
Upside: +72.79%